Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301893 | 0.92 | TUBB1 (0.39) | TUBB1PKMKMT2AKDM4EGAA | |
| SCHEMBL10301898 | 0.91 | TUBB1 (0.39) | TUBB1KMT2AGAAMEN1CD274 | |
| SCHEMBL10301894 | 0.90 | TUBB1 (0.38) | TUBB1PKMKMT2AMEN1KDM1A | |
| SCHEMBL10301895 | 0.87 | TUBB1 (0.36) | TUBB1KMT2AMEN1TOP2A | |
| SCHEMBL10302965 | 0.86 | TUBB1 (0.53) | TUBB1KMT2ATNFRSF1AKDM1A | |
| SCHEMBL10301900 | 0.86 | TUBB1 (0.40) | TUBB1KMT2AMEN1TNFRSF1AKDM1A | |
| SCHEMBL12739049 | 0.86 | TUBB1 (0.40) | TUBB1PKMKMT2AKDM4EGAA | |
| SCHEMBL10302984 | 0.85 | TUBB1 (0.37) | TUBB1PKMKMT2AKDM4EGAA | |
| SCHEMBL12739050 | 0.84 | TUBB1 (0.42) | TUBB1KMT2AKDM4EMEN1TNFRSF1A | |
| SCHEMBL12739045 | 0.84 | TUBB1 (0.42) | TUBB1KMT2AMEN1TNFRSF1AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | TUBB1 548/4885PKM 3690/4885KMT2A 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.